Search Site

Hasan Orhan Akman, PhD

  • Assistant Professor of Neurology
Hasan Orhan Akman, PhD

I am working on diagnosis and treatment of metabolic disorders that cause neuromuscular diseases, particularly glycogen storage disorders. Glycogen is the main form of carbohydrate storage in animals (starch in plants with less branched form) and occurs primarily in the liver and muscle tissue. It is readily converted to glucose as needed by the body to satisfy its energy needs. The synthesis of glycogen is catalyzed by the sequential action of two enzymes: (i) glycogen synthetase which attaches glucose molecules together, after approximately 7 to 11 glucose units added (ii) the branching enzyme hydrolyzes approximately 4 glucose unit long chain and attaches to same or adjacent chain. This branching activity is very important to synthesize soluble and functional glycogen molecule. In case of lower activity or absence of the glycogen branching enzyme, an abnormal very long branched polyglucosan accumulates in multiple tissues including liver, central nervous system, skeletal and heart muscles and cause glycogen storage disease (GSD) type IV (OMIM232500). Since the carriers are not affected this is an autosomal recessive disorder. Absence of enzyme activity (Anderson's disease) is embryonic lethal due to liver, heart and muscle failure. 10 to 15% of normal branching activity leads to a late onset clinical variant known as adult polyglucosan body disease (APBD) and progress as a neurodegenerative disorder.

Our goal is to produce an animal model for APBD that can be used in experiments to understand the mechanism of the disease and develop methods and pharmaceutical reagents for the treatment. In order to achieve this goal we introduced a common human mutation, which substitutes 329th amino acid tyrosine with serine, in to mouse GBE1 gene. Affected animals have very severe accumulation of polyglucosan bodies in muscle heart, liver and to a lesser extend in spinal cord. Currently we are breeding those animals in order to characterize the effect of mutation in their neuromuscular functions and behavior. In collaboration with Dr Minassian (Hospital of Sick Children at Toronto, Ontario CA) we will try FDA approved chemicals to stop the accumulation of polyglucosan bodies in those animals. In two years we may have a compound which can prevent polyglucosan formation in tissue. In our laboratory we will also try different approaches that help the cells to breakdown polyglucosan bodies. All together these experiments will yield invaluable information for the behavior of the accumulated material in the cells and ways to eliminate them. Our methods might be applied to other storage diseases like Pompeii (GSD II), Alzheimer, Parkinson and Huntington's diseases.

Departmental Appointments

  • Department of Neurology
    Division of Neuromuscular Medicine

NIH Grants

  • NAMDC: OVERALL RESEARCH PLAN (Federal Gov)

    Sep 1 2014 - Aug 31 2019

    MITOCHONDRIAL ENCEPHALOMYOPATHIES: APPROACHES TO TREATMENT (Federal Gov)

    Sep 30 2014 - May 31 2019

    TREATMENT OF ADULT POLYGLUCOSAN BODY DISEASE CAUSED BY INTRONIC MUTATION IN GLYCOGEN BRANCHING ENZYME (Private)

    Jul 1 2016 - Jun 30 2017

    MITOCHONDRIAL ENCEPHALOMYOPATHIES AND MENTAL RETARDATION (Federal Gov)

    Dec 1 1996 - Feb 29 2016

    DEVELOPMENT OF A COMPLETE PIPELINE FOR MELAS DRUG DISCOVERY (Private)

    Jan 1 2014 - Dec 31 2015

    METABOLITE BIOMARKER DISCOVERY IN MELAS (Private)

    Jan 1 2014 - Dec 31 2015

    POLYGLUCOSAN HAS NEUROTOXIC PROPERTIES THAT CAN BE CURED BY ELIMINATING GLYCOGEN SYNTHESIS OR RESTORING PROPER GLYCOGEN SYNTHESIS (Private)

    Nov 22 2013 - Nov 21 2014

    THERAPEUTIC STRATEGIES IN NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY (Private)

    Feb 1 2012 - Jan 31 2014

    PROPOSAL TO TEST SMALL MOLECULES TO CLEAR POLYGLUCOSAN (Private)

    Apr 1 2011 - Aug 31 2013

    COORDINATING CENTER FOR PEDIATRIC HIV/AIDS COHORT STUDY (PHACS) (Federal Gov)

    Sep 1 2010 - Aug 31 2012

    GENERATION AND CHARACTERIZATION OF A MOUSE MODEL OF ADULT PO LYGLUCOSAN BODY DISEASE (Private)

    Jan 1 2011 - Feb 28 2012